Spasticity Treatment During COVID-19 Pandemic: Clinical Recommendations
Authors:
Open Access
- 23 June 2020
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 11, 719
Abstract
Spasticity Treatment During COVID-19 Pandemic: Clinical RecommendationsKeywords
This publication has 17 references indexed in Scilit:
- Adjuvant treatments associated with botulinum toxin injection for managing spasticity: An overview of the literatureAnnals of Physical and Rehabilitation Medicine, 2019
- Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapyJournal of Neurology, 2018
- Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term ManagementNeuromodulation: Technology at the Neural Interface, 2016
- The management of spasticity in adultsBMJ, 2014
- Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic reviewNeuropsychiatric Disease and Treatment, 2014
- The impact of spasticity severity on healthcare utilization among MS patients: A large-scale six-year follow-up studyJournal of the Neurological Sciences, 2013
- Anxiety and Depression Associated With Caregiver Burden in Caregivers of Stroke Survivors With SpasticityArchives of Physical Medicine and Rehabilitation, 2013
- Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndromeToxicon, 2013
- Spasticity: pathophysiology, evaluation and managementPractical Neurology, 2012
- European consensus table on the use of botulinum toxin type A in adult spasticityJournal of Rehabilitation Medicine, 2009